Research analysts covering YD Bio.
Recent press releases and 8-K filings for YDES.
YD Bio Limited Enters Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co.
YDES
M&A
New Projects/Investments
- YD Bio Limited announced on January 29, 2026, that it entered a binding Letter of Intent on January 20, 2026, to acquire 100% of Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC).
- SSMC is a Taiwan-based dendritic cell immunotherapy platform specializing in therapeutic drugs using its proprietary Autologous Dendritic Cells/Tumor Antigens (ADCTA) technology.
- The acquisition, valued at approximately US$26.87 million (NT$839,832,000), will be paid in a mix of cash and YD Bio Ltd ordinary shares, and is expected to enhance YD Bio Ltd's R&D capabilities and expand its therapeutic solutions beyond diagnostics.
- The parties aim to complete due diligence by March 20, 2026, with the transaction anticipated to close within 30 days thereafter, subject to customary closing conditions.
8 days ago
YD Bio Limited Outlines Strategic Transformation and Reports Strong Revenue Growth
YDES
New Projects/Investments
M&A
Revenue Acceleration/Inflection
- YD Bio Limited is undergoing a strategic transformation to become an end-to-end biotechnology ecosystem, integrating regulated diagnostics, commercialization platforms, clinical execution capabilities, and life science services.
- The company reported a 46% increase in net revenue, rising from $350,131 thousand for the year ended December 31, 2023, to $510,360 thousand for the year ended December 31, 2024.
- In 2024, medical and related products were the primary revenue driver, accounting for 57.4% of total revenue.
- YD Bio has established partnerships with EG BioMed Co., Ltd. for DNA methylation-based oncology testing and 3D Global Biotech Inc. for exosome programs.
- For 2026, the company plans to focus on strengthening clinical evidence generation, regulatory planning, and U.S. commercialization, while also evaluating strategic acquisitions to enhance platform capabilities.
Jan 15, 2026, 4:40 PM
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results and Business Combination Completion
YDES
Earnings
New Projects/Investments
M&A
- YD Biopharma Limited reported a 9% decrease in net revenue to $204,007 for the six months ended June 30, 2025, down from $224,980 in the prior year.
- The company's net loss significantly increased to $(1,916,581) for the six months ended June 30, 2025, compared to $(165,364) in the prior period, primarily due to higher general and administrative and research and development expenses.
- Cash and cash equivalents for YD Biopharma Limited decreased to $469,520 as of June 30, 2025, from $3,132,298 at December 31, 2024.
- YD Bio Limited completed its business combination with Breeze Holdings Acquisition Corp. in August 2025, becoming a publicly traded company and securing $13.2 million in gross proceeds from a concurrent PIPE financing.
- The company is advancing its pipeline with new projects, including initiating clinical trial applications in 2025 for exosome-based contact lenses and artificial tears for dry eye symptoms, and expanding into oncology diagnostics with a pancreatic cancer early detection technology.
Sep 30, 2025, 8:30 PM
YD Bio Limited Completes Business Combination and Lists on Nasdaq
YDES
M&A
New Projects/Investments
Delisting/Listing Issues
- YD Bio Limited successfully completed its business combination with Breeze Holdings Acquisition Corp. and began trading its common stock and warrants on the Nasdaq Global Market under the ticker symbols "YDES" and "YDESW" on August 29, 2025.
- The company expects to yield more than $11,500,000 from the PIPE offering and cash released from the trust, after business combination closing-related expenses, to fund future operations.
- YD Bio Ltd. is a biotechnology company focused on advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, with core programs including blood-based cancer detection, stem cell- and exosome-based ophthalmology therapies, and clinical trial and ancillary services.
- Dr. Ethan Shen, Chairman of the Board and Chief Executive Officer, stated that becoming a publicly traded Nasdaq-listed company enables the company to accelerate its mission of delivering innovative solutions.
Aug 29, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more